RLMD
Relmada Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.43
+1.37%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-30.0%
Return on equity
-28.3%
Return on assets
-31.5%
Return on invested capital
0.00x
Asset turnover
-$46.0M
Cash from operations
$2.04
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026